Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VEEVA SYSTEMS INC.

(VEEV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Veeva : 2021 Veeva Heroes Enable Better, More Patient-Focused Drug Development

06/16/2021 | 04:08pm EDT

Drug development professionals triumphed in 2020, breaking through limits set by COVID-19 to achieve amazing results. They challenged norms, shared a clear vision of the future, and worked tirelessly to enact that vision during a year filled with uncertainties.

At this year's Veeva 2021 R&D and Quality Summit, Europe, we recognized the achievements of five heroes who are having a significant impact within their companies and beyond. Each of them is championing smarter use of data to help R&D and quality programs reach their full potential. Their efforts continue to bring greater patient focus and willingness to try new approaches to the life sciences industry. Here are their stories.


Tanya du Plessis, Vice President of Data Strategies and Solutions,
Bioforum, The Data Masters

Evangelist for clinical data innovation and strategy

At a time when many companies still handle clinical data manually and on paper, Tanya has been a staunch advocate for innovation and improved data management. Her message to pharma companies is consistent: Plan strategically and based on your unique needs. It is reinforced in webinars, columns advising emerging biotech companies, and in presentations delivered through the Society for Clinical Data Management. Tanya is also an expert in system validation strategy, and advises others within the industry on best practices.

Tanya was an early proponent of clinical data management systems (CDMS). At Bioforum, her focus on risk-based quality management has brought significant improvements to the way the company and its clients manage clinical data. Under Tanya's leadership, Bioforum became one of the first CROs in the industry to use modern electronic data capture (EDC) approaches, replacing outdated EDC technology that had required custom programming and extensive effort to support. After Tanya and her team rolled out Veeva Vault EDC in 2020, Bioforum increased the speed of clinical trial builds by 35% and of amendments by 70%.

Bioforum CEO Amir Malka spoke for many at the company when he said, 'Tanya pushes us all to challenge the status quo and to be open to doing things in new and different ways for the benefit of the patients we serve.'


Françoise Brunengo, Project Manager, Health Economics and Outcomes Research,
Pierre Fabre

Change agent for data governance and standardization

Francoise recognized that siloed and manual approaches to managing regulatory data need to change. This is especially true as global regulatory agencies raise their expectations for data governance and the digitizing and standardization of pharmaceutical data. Her commitment to streamlining regulatory data management led to increased efficiency across GxP functions at Pierre Fabre. These improvements will prepare the company to meet evolving standards such as the International Organization for Standardization's Identification of Medicinal Products (IDMP), which aims to improve pharmacovigilance, compliance, and transparency within the industry.

Françoise articulated a clear data management vision for regulatory affairs and governance, convincing colleagues and senior managers alike of the need for more modern, streamlined approaches. She was a leader in the company's implementation of Veeva Vault RIM, which replaced manual processes based on outdated technology.

According to Nathalie Thomas Pujol, the company's head of regulatory affairs, 'Françoise understood the value of the transformation and could explain why it was necessary. She was more than a key contributor to the success of the RIM project; she enthusiastically supported the application's adoption by future users.'


Astrid Bériaux, Director of Clinical Documentation,
GSK

Clinical operations visionary takes on harmonization

At many pharma companies today, clinical operations are constrained by manual and paper-based processes, which distract clinicians from science and analysis, and increase the risk of noncompliance. At GSK, Astrid saw a need to improve the way that clinical data and operations were managed. She advocated a streamlined approach that would enable proactive compliance and convinced management of the need to change established practices. A crucial part of her vision was moving to a modern electronic Trial Master File (eTMF) solution. Under her leadership, GSK's vaccines division rolled out Veeva Vault eTMF.

Astrid believed that this modern approach to clinical operations documentation could also benefit GSK's pharma division and convinced managers that it would work. Eventually, GSK's pharma and consumer healthcare divisions also adopted Veeva Vault eTMF.

Astrid and her team's efforts harmonized clinical documentation and work processes for GSK's vaccine, pharma, and consumer healthcare divisions, laying the foundation for stronger collaboration in the future. Colleagues have praised this project as one of the company's smoothest technology implementations to date. 'Astrid led an ambitious global rollout for three separate business units. She aligned the teams around a shared vision and proactively anticipated challenges through careful planning and decisive leadership,' said Simon J. Trowell, GSK's vice president of quality, capability, and risk management.


Victoria Stace,
Director, Strategic Advice, Quality Assurance,
AstraZeneca

Innovative thinker and catalyst for unified quality management

Regulatory agencies often cite pharma companies for inadequate CAPA and quality documentation. In many cases, these issues can be traced to the way that quality data is kept, exchanged, and stored. Moving to streamlined processes and improved quality management systems (QMS) can ease compliance by automating data access and other functions-something Victoria recognized early on.

Victoria saw an opportunity to improve AstraZeneca's overall quality and compliance efforts by strengthening its management of audits, inspections, quality issues, and CAPA programs. She and her team evaluated different QMS platforms and selected Veeva Vault QMS, rolling out the application within eight months. As a result, AstraZeneca has already improved its oversight of quality events and CAPA completion rates with improved escalation and reporting, speeding clinical study protocol processes for 40,000 users throughout the company.

Colleagues have been enthusiastic about the new application. 'It provides a step change in our ability to provide assurance and to partner proactively with stakeholders to share data-driven insights, advice, and expertise,' commented Graeme Downes, senior director of clinical and pharmacovigilance quality assurance. He also praised Victoria for her 'dynamic leadership and innovative thinking.'


Michael Buch-Hansen, Senior Project Manager,
Novo Nordisk

Innovative thinker and catalyst for unified quality management

Many companies still struggle with the silos that separate functions-and people-within R&D. Michael realized that fragmented applications and outdated systems would not sustain Novo Nordisk's growth and the company's ambitious plans to automate more drug development functions.

Michael's quest for better data connectivity between key functional areas in drug development led him to Veeva Development Cloud, which he and his team implemented across the company's clinical, quality, and regulatory functions. During this process, Michael also developed a novel approach to improve data governance across the new applications.

'Michael is highly respected within IT and the business for his ability to drive progress on key programs,' said Ulla Outtrup, corporate vice president. One of many positive results of Michael's work was the establishment of a global platform team at Novo Nordisk, dedicated to ensuring consistency in the way that the company works with all R&D data applications.

For more insights into how life sciences companies are streamlining drug development and quality operations, view sessions from Veeva's 2021 EU R&D and Quality Summit.

Disclaimer

Veeva Systems Inc. published this content on 16 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 June 2021 20:07:08 UTC.


ę Publicnow 2021
All news about VEEVA SYSTEMS INC.
07/27VEEVA : Enhancing HCP Engagement With a Hybrid Events Strategy
PU
07/21VEEVA : Royal Bank of Canada Initiates Veeva Systems at Outperform With $400 Pri..
MT
07/15MODERNIZING REGULATORY AFFAIRS : Veeva MedTech Regulatory Benchmark Study
PU
07/15VEEVA : Biopharma Leaders Pioneering a Digital-First Future for Commercial
PU
07/14VEEVA : How Biopharma Leaders are Shifting to Hybrid Engagement
PU
07/09VEEVA : Lessons from Vericel on Streamlining Medical Information Management
PU
07/06VEEVA : Cutting Through the Noise With Predictive Pharmacovigilance
PU
07/06INSIDER TRENDS : Veeva Systems Insider Exercises Option/Derivative Security to A..
MT
07/06INSIDER TRENDS : Insider at Veeva Systems Acquires Stock Via Option/Derivative S..
MT
07/02VEEVA : How Life Sciences' Shift to Digital is Improving Collaboration and Patie..
PU
More news
Financials (USD)
Sales 2022 1 823 M - -
Net income 2022 443 M - -
Net cash 2022 2 411 M - -
P/E ratio 2022 119x
Yield 2022 -
Capitalization 50 878 M 50 878 M -
EV / Sales 2022 26,6x
EV / Sales 2023 22,0x
Nbr of Employees 4 506
Free-Float 89,7%
Chart VEEVA SYSTEMS INC.
Duration : Period :
Veeva Systems Inc. Technical Analysis Chart | VEEV | US9224751084 | MarketScreener
Technical analysis trends VEEVA SYSTEMS INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 332,71 $
Average target price 334,55 $
Spread / Average Target 0,55%
EPS Revisions
Managers and Directors
Peter P. Gassner Chief Executive Officer & Director
Tom Schwenger President & Chief Operating Officer
Brent Bowman Chief Financial Officer
Gordon Ritter Chairman
Catherine Allshouse Global Chief Information Officer & Head-Operations
Sector and Competitors
1st jan.Capi. (M$)
VEEVA SYSTEMS INC.22.21%50 878
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED-47.25%20 948
OMNICELL, INC.22.06%6 327
PRO MEDICUS LIMITED69.73%4 439
CLOVER HEALTH INVESTMENTS, CORP.-51.88%3 293
SECTRA AB (PUBL)-6.48%3 073